Australia Fusion Biopsy Market Size & Outlook, 2023-2030
Australia fusion biopsy market, 2018-2030 (US$M)
Related Markets
Australia fusion biopsy market highlights
- The Australia fusion biopsy market generated a revenue of USD 10.0 million in 2023 and is expected to reach USD 18.4 million by 2030.
- The Australia market is expected to grow at a CAGR of 9.1% from 2024 to 2030.
- In terms of segment, transrectal was the largest revenue generating biopsy route in 2023.
- Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.
Fusion biopsy market data book summary
| Market revenue in 2023 | USD 10.0 million |
| Market revenue in 2030 | USD 18.4 million |
| Growth rate | 9.1% (CAGR from 2023 to 2030) |
| Largest segment | Transrectal |
| Fastest growing segment | Transperineal |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transrectal, Transperineal |
| Key market players worldwide | Koninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care |
Other key industry trends
- In terms of revenue, Australia accounted for 1.6% of the global fusion biopsy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan fusion biopsy market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 67.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fusion Biopsy Market Scope
Fusion Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia fusion biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.
Transrectal was the largest segment with a revenue share of 85% in 2023. Horizon Databook has segmented the Australia fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.
The growing incidence of prostate cancer and the increasing geriatric population are expected to drive the market over the forecast period. According to Cancer Australia, there were 16,741 new cases of prostate cancer in males reported in 2020.
It is estimated to become the second most commonly diagnosed cancer in 2020. Thus, the above-mentioned factor is expected to boost the demand for the fusion biopsy market in the country.
Reasons to subscribe to Australia fusion biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia fusion biopsy market databook
-
Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia fusion biopsy market , including forecasts for subscribers. This country databook contains high-level insights into Australia fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia fusion biopsy market size, by biopsy route, 2018-2030 (US$M)
Australia Fusion Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
